ArticleNature communications2017
Long-acting protein drugs for the treatment of ocular diseases.
Article in Nature communications, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 54 citations in OpenAlex.
- Atropine-Loaded Contact Lens Sustained-Release Systems: A Narrative Review for the New Frontier for Myopia Management.Ophthalmology and therapy · 2026Review
- Drug Delivery Technologies for the Treatment of Age-Related Macular Degeneration.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Local controlled release of stabilized monoclonal antibodies.Journal of controlled release : official journal of the Controlled Release Society · 2025Article
- Fish Fin-Derived Non-Invasive Flexible Bioinspired Contact Lens for Continuous Ophthalmic Drug Delivery.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exploring How Antibody Format Drives Clearance from the Brain.Molecular pharmaceutics · 2024Article
- Antibody blockade of Jagged1 attenuates choroidal neovascularization.Nature communications · 2023Article
- Evaluation of Molecular Properties versus In Vivo Performance of Aflibercept, Brolucizumab, and Ranibizumab in a Retinal Vascular Hyperpermeability Model.Translational vision science & technology · 2022Article
- Protein and polypeptide mediated delivery to the eye.Advanced drug delivery reviews · 2022Review
- Pigment epithelium-derived factor engineered to increase glycosaminoglycan affinity while maintaining bioactivity.Biochemical and biophysical research communications · 2022Article
- Biodegradable silicon nanoneedles for ocular drug delivery.Science advances · 2022Article
- Hyaluronic Acid-Based Nanomaterials as a New Approach to the Treatment and Prevention of Bacterial Infections.Frontiers in bioengineering and biotechnology · 2022Review
- Peptide Inhibitors of Vascular Endothelial Growth Factor A: Current Situation and Perspectives.Pharmaceutics · 2021Review
- Harnessing molecular recognition for localized drug delivery.Advanced drug delivery reviews · 2021Review
- Injectables and Depots to Prolong Drug Action of Proteins and Peptides.Pharmaceutics · 2020Review
- Toward Drug-Like Multispecific Antibodies by Design.International journal of molecular sciences · 2020Review
- Understanding the Half-Life Extension of Intravitreally Administered Antibodies Binding to Ocular Albumin.Pharmaceutics · 2020Article
- Hydrodynamics of Intravitreal Injections into Liquid Vitreous Substitutes.Pharmaceutics · 2019Article
- Intra-vitreal αB crystallin fused to elastin-like polypeptide provides neuroprotection in a mouse model of age-related macular degeneration.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Extended Intravitreal Rabbit Eye Residence of Nanoparticles Conjugated With Cationic Arginine Peptides for Intraocular Drug Delivery: In Vivo Imaging.Investigative ophthalmology & visual science · 2018Article
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'.Nature reviews. Drug discovery · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein drugs that neutralize vascular endothelial growth factor (VEGF), such as aflibercept or ranibizumab, rescue vision in patients with retinal vascular diseases. Nonetheless, optimal visual outcomes require intraocular injections as frequently as every month. Here we report a method to extend the intravitreal half-life of protein drugs as an alternative to either encapsulation or chemical modifications with polymers. We combine a 97-amino-acid peptide of human origin that binds hyaluronan, a major macromolecular component of the eye's vitreous, with therapeutic antibodies and proteins. When administered to rabbit and monkey eyes, the half-life of the modified proteins is increased ∼3-4-fold relative to unmodified proteins. We further show that prototype long-acting anti-VEGF drugs (LAVAs) that include this peptide attenuate VEGF-induced retinal changes in animal models of neovascular retinal disease ∼3-4-fold longer than unmodified drugs. This approach has the potential to reduce the dosing frequency associated with retinal disease treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.